HF
CRSP icon

HRT Financial’s CRISPR Therapeutics CRSP Stock Holding History

HRT Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.35M Buy
70,532
+42,560
+152% +$2.24M 0.01% 1247
2025
Q4 		$1.47M Buy
+27,972
New +$1.68M ﹤0.01% 1498
2025
Q2 		– Sell
-90,915
Closed -$3.09M – 2765
2025
Q1 		$3.09M Buy
90,915
+82,277
+953% +$3.49M 0.02% 624
2024
Q4 		$339K Buy
+8,638
New +$408K ﹤0.01% 1648
2024
Q2 		– Sell
-69,429
Closed -$4.73M – 2355
2024
Q1 		$4.73M Buy
+69,429
New +$4.97M 0.03% 276
2023
Q3 		– Sell
-14,093
Closed -$791K – 2502
2023
Q2 		$791K Sell
14,093
-21,391
-60% -$1.21M 0.01% 1094
2023
Q1 		$1.6M Buy
35,484
+21,400
+152% +$1.04M 0.02% 715
2022
Q4 		$572K Buy
+14,084
New +$747K 0.01% 1322
2021
Q3 		– Sell
-101,731
Closed -$16.5M – 3355
2021
Q2 		$16.5M Buy
101,731
+91,222
+868% +$11.1M 0.15% 113
2021
Q1 		$1.28M Buy
+10,509
New +$1.59M 0.01% 917
2020
Q3 		– Sell
-3,766
Closed -$276K – 1961
2020
Q2 		$276K Buy
+3,766
New +$220K 0.01% 1022
2019
Q1 		– Sell
-10,381
Closed -$296K – 564
2018
Q4 		$296K Buy
+10,381
New +$361K 0.04% 358

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HRT Financial's CRSP Position: Q1 2026 in Review

HRT Financial increased its CRISPR Therapeutics (CRSP) stake by 152% in Q1 2026, buying an estimated $2.24M and bringing the position to 70,532 shares worth $3.35M. The position accounts for 0.01% of the portfolio, ranked #1247.

HRT Financial first reported a position in CRSP in Q4 2018 and has held it in 12 quarters since. The position peaked at $16.5M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • HRT Financial held 70,532 shares of CRISPR Therapeutics worth $3.35M as of Q1 2026.
  • HRT Financial bought 42,560 CRISPR Therapeutics shares in Q1 2026, an estimated $2.24M.
  • CRISPR Therapeutics made up 0.01% of HRT Financial's portfolio in Q1 2026, its #1247 holding.
  • HRT Financial first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 12 quarters since.
  • HRT Financial's CRISPR Therapeutics position peaked at $16.5M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.